SI2408775T1 - Oksidirani derivati triazolilpurinov, ki so uprabni kot ligandi receptorja adenozina A2A, in njihova uporaba kot zdravila - Google Patents
Oksidirani derivati triazolilpurinov, ki so uprabni kot ligandi receptorja adenozina A2A, in njihova uporaba kot zdravilaInfo
- Publication number
- SI2408775T1 SI2408775T1 SI201030983T SI201030983T SI2408775T1 SI 2408775 T1 SI2408775 T1 SI 2408775T1 SI 201030983 T SI201030983 T SI 201030983T SI 201030983 T SI201030983 T SI 201030983T SI 2408775 T1 SI2408775 T1 SI 2408775T1
- Authority
- SI
- Slovenia
- Prior art keywords
- triazolylpurines
- adenosine
- medicaments
- ligands
- receptor
- Prior art date
Links
- 102000007471 Adenosine A2A receptor Human genes 0.000 title 1
- 108010085277 Adenosine A2A receptor Proteins 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09155690 | 2009-03-20 | ||
| PCT/EP2010/053554 WO2010106145A1 (en) | 2009-03-20 | 2010-03-18 | Oxidated derivatives of triazolypurines useful as ligands of the adenosine a2a receptor and their use as medicaments |
| EP10709526.7A EP2408775B1 (en) | 2009-03-20 | 2010-03-18 | Oxidated derivatives of triazolylpurines useful as ligands of the adenosine a2a receptor and their use as medicaments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2408775T1 true SI2408775T1 (sl) | 2015-08-31 |
Family
ID=40941572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201030983T SI2408775T1 (sl) | 2009-03-20 | 2010-03-18 | Oksidirani derivati triazolilpurinov, ki so uprabni kot ligandi receptorja adenozina A2A, in njihova uporaba kot zdravila |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9133197B2 (sl) |
| EP (1) | EP2408775B1 (sl) |
| JP (1) | JP5648044B2 (sl) |
| AR (1) | AR075894A1 (sl) |
| DK (1) | DK2408775T3 (sl) |
| ES (1) | ES2542555T3 (sl) |
| HR (1) | HRP20150766T1 (sl) |
| HU (1) | HUE025704T2 (sl) |
| PL (1) | PL2408775T3 (sl) |
| PT (1) | PT2408775E (sl) |
| SI (1) | SI2408775T1 (sl) |
| SM (1) | SMT201500174B (sl) |
| TW (1) | TWI473809B (sl) |
| WO (1) | WO2010106145A1 (sl) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11312783B2 (en) | 2017-06-22 | 2022-04-26 | Novartis Ag | Antibody molecules to CD73 and uses thereof |
| EP3642240A1 (en) | 2017-06-22 | 2020-04-29 | Novartis AG | Antibody molecules to cd73 and uses thereof |
| SG11202002886PA (en) * | 2017-09-28 | 2020-04-29 | Cstone Pharmaceuticals Suzhou Co Ltd | Fused ring derivative as a2a receptor inhibitor |
| WO2019099838A1 (en) | 2017-11-16 | 2019-05-23 | Novartis Ag | Combination therapies |
| EP3717907A1 (en) | 2017-11-30 | 2020-10-07 | Novartis AG | Bcma-targeting chimeric antigen receptor, and uses thereof |
| US10738128B2 (en) | 2018-03-14 | 2020-08-11 | Surface Oncology, Inc. | Antibodies that bind CD39 and uses thereof |
| UY38247A (es) | 2018-05-30 | 2019-12-31 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| KR20210016390A (ko) | 2018-06-01 | 2021-02-15 | 노파르티스 아게 | Bcma에 대한 결합 분자 및 이의 용도 |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| CN113271945A (zh) | 2018-12-20 | 2021-08-17 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合 |
| EP3924054A1 (en) | 2019-02-15 | 2021-12-22 | Novartis AG | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| US20220144798A1 (en) | 2019-02-15 | 2022-05-12 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| EP4031178A1 (en) | 2019-09-16 | 2022-07-27 | Surface Oncology, Inc. | Anti-cd39 antibody compositions and methods |
| TW202124446A (zh) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | 與ｅｎｔｐｄ２抗體之組合療法 |
| EP4031578A1 (en) | 2019-09-18 | 2022-07-27 | Novartis AG | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
| CN115087671A (zh) | 2019-09-25 | 2022-09-20 | 表面肿瘤学公司 | 抗il-27抗体及其用途 |
| IL293834A (en) | 2019-12-20 | 2022-08-01 | Novartis Ag | A combination of anti-tim-3 antibody mbg453 and anti, nis793 tgf-beta antibody with or without decitabine or anti-pd-1 antibody spratlizumab, for the treatment of myelofibrosis and myelodysplastic syndrome |
| US20230321067A1 (en) | 2020-06-23 | 2023-10-12 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| AU2021373366A1 (en) | 2020-11-06 | 2023-06-01 | Novartis Ag | Cd19 binding molecules and uses thereof |
| JP2024505049A (ja) | 2021-01-29 | 2024-02-02 | ノバルティス アーゲー | 抗ｃｄ７３及び抗ｅｎｔｐｄ２抗体のための投与方式並びにその使用 |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2315736A1 (en) * | 1998-01-05 | 1999-07-15 | Eisai Co., Ltd. | Purine compounds and adenosine a2 receptor antagonist as preventive or therapeutic for diabetes mellitus |
| JP3990061B2 (ja) * | 1998-01-05 | 2007-10-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | プリン誘導体および糖尿病の予防・治療剤としてのアデノシンａ２受容体拮抗剤 |
| JP4324338B2 (ja) * | 1999-07-02 | 2009-09-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 縮合イミダゾール化合物及び糖尿病治療薬 |
| ES2307593T3 (es) * | 2000-02-10 | 2008-12-01 | New York University | Antagonistas del receptor a2a de adenosina para el tratamiento y la prevencion de la fibrosis hepatica, la cirrosis y la esteatosis hepatica. |
| KR100897219B1 (ko) * | 2001-06-29 | 2009-05-14 | 씨브이 쎄러퓨틱스, 인코포레이티드 | Ａ２ｂ 아데노신 수용체 길항제로서의 퓨린 유도체 |
| ITRM20010465A1 (it) * | 2001-07-31 | 2003-01-31 | Sigma Tau Ind Farmaceuti | Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam |
| JPWO2003020723A1 (ja) * | 2001-08-30 | 2004-12-16 | 協和醗酵工業株式会社 | ［１，２，４］トリアゾロ［１，５−ａ］ピリミジン誘導体 |
| GB0500785D0 (en) * | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
| JPWO2006129626A1 (ja) * | 2005-05-30 | 2009-01-08 | 協和醗酵工業株式会社 | ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体の製造法 |
-
2010
- 2010-03-18 HU HUE10709526A patent/HUE025704T2/en unknown
- 2010-03-18 EP EP10709526.7A patent/EP2408775B1/en active Active
- 2010-03-18 US US13/257,750 patent/US9133197B2/en not_active Expired - Fee Related
- 2010-03-18 SI SI201030983T patent/SI2408775T1/sl unknown
- 2010-03-18 PT PT107095267T patent/PT2408775E/pt unknown
- 2010-03-18 WO PCT/EP2010/053554 patent/WO2010106145A1/en active Application Filing
- 2010-03-18 JP JP2012500259A patent/JP5648044B2/ja not_active Expired - Fee Related
- 2010-03-18 PL PL10709526T patent/PL2408775T3/pl unknown
- 2010-03-18 ES ES10709526.7T patent/ES2542555T3/es active Active
- 2010-03-18 DK DK10709526.7T patent/DK2408775T3/en active
- 2010-03-19 TW TW99108187A patent/TWI473809B/zh not_active IP Right Cessation
- 2010-03-19 AR ARP100100883A patent/AR075894A1/es unknown
-
2015
- 2015-07-13 HR HRP20150766TT patent/HRP20150766T1/hr unknown
- 2015-07-20 SM SM201500174T patent/SMT201500174B/xx unknown
- 2015-08-10 US US14/822,252 patent/US20160002244A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012520854A (ja) | 2012-09-10 |
| HRP20150766T1 (hr) | 2015-08-14 |
| EP2408775A1 (en) | 2012-01-25 |
| DK2408775T3 (en) | 2015-07-27 |
| US20120053191A1 (en) | 2012-03-01 |
| ES2542555T3 (es) | 2015-08-06 |
| TW201100425A (en) | 2011-01-01 |
| SMT201500174B (it) | 2015-10-30 |
| HUE025704T2 (en) | 2016-04-28 |
| JP5648044B2 (ja) | 2015-01-07 |
| EP2408775B1 (en) | 2015-06-17 |
| WO2010106145A1 (en) | 2010-09-23 |
| US9133197B2 (en) | 2015-09-15 |
| PT2408775E (pt) | 2015-08-05 |
| AR075894A1 (es) | 2011-05-04 |
| TWI473809B (zh) | 2015-02-21 |
| PL2408775T3 (pl) | 2015-10-30 |
| US20160002244A1 (en) | 2016-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2408775T3 (pl) | Utlenione pochodne triazolilopurynowe użyteczne jako ligandy receptora adenozynowego a2a i ich zastosowanie jako leków | |
| IL250435A0 (en) | Using hil-2-mutein of human origin to prepare a factor for the production of regulatory t cells | |
| PL2552909T3 (pl) | Pochodne 4-aminopirymidyny i ich zastosowanie jako antagonistów receptorów adenozynowych a2a | |
| IL221160A (en) | 4,2,1-triazine-3-amine derivatives, a process for their preparation and use for drug preparation | |
| ZA201206062B (en) | Aminotetraline derivatives,pharmaceutical compositions containing them,and their use in therapy | |
| HK1153926A1 (en) | Purin derivatives for use in the treatment of fab-related diseases fab- | |
| ZA201000075B (en) | Purin derivatives for use in the treatment of fab-related diseases | |
| IL217490A (en) | History of pyridine-4-il, pharmaceutical preparations containing them and their use in the preparation of medicines | |
| IL216609A0 (en) | Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives | |
| HK1167392A1 (en) | Adenosine receptor ligands and uses thereof | |
| ZA201004227B (en) | Bicyclic derivatives for use in the treatment of androgen receptor associated conditions | |
| ZA201002959B (en) | Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119 | |
| EP2188295A4 (en) | PYRIDINE DERIVATIVES AND METHODS OF USE | |
| IL219120A (en) | Cyclohaphtha pyridinyl derivatives and their use in drug preparation | |
| IL215690A0 (en) | Thiazole derivatives and their use as p2y12 receptor antagonists | |
| IL205608A (en) | History of s-triazole-1-ram-benzamide and their use in the preparation of pain medication | |
| IL219888A0 (en) | Pyridine-pyridinone derivatives, preparation and therapeutic use thereof | |
| HK1169388A1 (en) | 6,7,8,9-tetrahydro-pyrimido1,2-a pyrimidin-4-one derivatives, their preparation and pharmaceutical use thereof 6789-12-a -4- | |
| EP2448944A4 (en) | Isomannide derivatives and their use as flavorings | |
| EP2621898A4 (en) | PROCESS FOR THE PREPARATION OF TETRACYCLIC DERIVATIVES AND INTERMEDIATE PRODUCTS USED IN THE PROCESS | |
| EP2460812A4 (en) | STEROL DERIVATIVES AND THEIR SYNTHESIS AND USE | |
| ZA201107883B (en) | Substituted 6-(2-hydroxybenzylamino)purine derivatives, their use as medicaments and compositions containint these derivatives | |
| ZA201104945B (en) | Substituted 6-(2-aminobenzylamino)purine derivatives, their use as medicaments and preparations containing these compounds | |
| IL219335A0 (en) | Alkyl substituted arylindenopyrimidines and their use as highly selective adennosine a2a receptor antsgonists | |
| HK1164861A1 (en) | Substituted 3-benzofuranyl-indol-2-one-3-acetamidopiperazine derivatives, preparation thereof, and therapeutic use thereof |